What you should know:
1. Conmed attributed the sales growth to its acquisitions, stating the acquisitions contributed to 300 basis points of growth.
2. The company’s domestic revenues increased 10.1 percent year over year.
3. Conmed reported diluted earnings per share of $0.04, which was down from the $0.37 per share for the same period of 2018.
4. Conmed’s orthopedic segment continued to drive growth. The orthopedic division had $113.4 million in sales, up from $108.9 million for the same period in 2018.
5. Conmed adjusted its future guidance expecting full-year sales growth in the range of 9-10 percent.
“We are pleased to report continued strength and momentum in the business this quarter,” said Conmed’s President and CEO Curt Hartman. “Our expanding new product pipeline, combined with our solid execution during the first quarter, positions us well to deliver on our increased expectations for 2019.”
More articles on devices:
UR Medicine Orthopaedics partners with Thompson Health to open new office
Rapid expansion for 7 Springs Orthopedics expected after closing investment — 4 insights
East Tennessee Center for Orthopaedic Excellence named 2019 Small Business of the Year by local chamber
